Ryuichi Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ryuichi Kato has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Genki Kobayashi
Department of Urology, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan
2 shared publications - Ko Kobayashi
Department of Urology Sapporo Medical University School of Medicine Sapporo Japan
2 shared publications - Kohei Hashimoto
Department of Urology Sapporo Medical University School of Medicine Sapporo Japan
2 shared publications - Naoya Masumori
Department of Urology Sapporo Medical University School of Medicine Sapporo Japan
2 shared publications - Shintaro Miyamoto
Department of Urology, Japanese Red Cross Asahikawa Hospital, Asahikawa 070-8530, Japan
2 shared publications - Tetsuya Shindo
Department of Urology Sapporo Medical University School of Medicine Sapporo Japan
2 shared publications
Latest Publications
- Open Access
Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit
Background: To clarify the timing of treatment initiation for non-metastatic castration-resistant prostate cancer (nmCRPC), we investigated the impact of baseline prostate-specific antigen (PSA) at treatment initiation on outcomes, the stability of PSADT estimation at low PSA levels, and the prognostic significance of PSADT. Methods: We retrospectively analyzed 129 consecutive nmCRPC patients between 2000 and 2023. All patients were divided by PSADT ≤ 10 months (n = 109) or >10 months (n = 20). PSA progression-free survival (PSA-PFS) and metastasis-free survival (MFS) were assessed by the Kaplan–Meier method, with predictive factors analyzed using Cox proportional hazards modeling. PSA-PFS was further compared across baseline PSA subgroups (10 ng/mL) in the PSADT ≤ 10 months cohort. Results: Patients with PSADT ≤ 10 months had worse MFS than patients with PSADT > 10 months (4-year: 71.9% vs. 100%; p = 0.021). In the PSADT ≤ 10 months group, novel androgen receptor pathway inhibitor (ARPI) treatment significantly improved PSA-PFS compared to those who did not (median: 44.0 vs. 16.6 months; p < 0.001). In multivariate analysis, prior definitive local therapy (Hazard Ratio [HR] 0.409, p < 0.001), ARPIs as first-line treatment (HR 0.421, p < 0.001) and lower baseline PSA at treatment initiation (HR 0.961, p = 0.004) were significantly predictive factors for PSA-PFS. PSADT estimation remained accurate when calculated from PSA nadir values ≥0.5 ng/mL. Conclusions: In patients with nmCRPC with PSADT ≤ 10 months, early initiation of ARPIs at lower PSA levels was associated with improved PSA-PFS. PSADT stabilized at PSA levels of >0.5 ng/mL. These findings support earlier ARPI initiation to optimize outcomes in high-risk nmCRPC.
Open AccessOptimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit
Background: To clarify the timing of treatment initiation for non-metastatic castration-resistant prostate cancer (nmCRPC), we investigated the impact of baseline prostate-specific antigen (PSA) at treatment initiation on outcomes, the stability of PSADT estimation at low PSA levels, and the prognostic significance of PSADT. Methods: We retrospectively analyzed 129 consecutive nmCRPC patients between 2000 and 2023. All patients were divided by PSADT ≤ 10 months (n = 109) or >10 months (n = 20). PSA progression-free survival (PSA-PFS) and metastasis-free survival (MFS) were assessed by the Kaplan–Meier method, with predictive factors analyzed using Cox proportional hazards modeling. PSA-PFS was further compared across baseline PSA subgroups (10 ng/mL) in the PSADT ≤ 10 months cohort. Results: Patients with PSADT ≤ 10 months had worse MFS than patients with PSADT > 10 months (4-year: 71.9% vs. 100%; p = 0.021). In the PSADT ≤ 10 months group, novel androgen receptor pathway inhibitor (ARPI) treatment significantly improved PSA-PFS compared to those who did not (median: 44.0 vs. 16.6 months; p < 0.001). In multivariate analysis, prior definitive local therapy (Hazard Ratio [HR] 0.409, p < 0.001), ARPIs as first-line treatment (HR 0.421, p < 0.001) and lower baseline PSA at treatment initiation (HR 0.961, p = 0.004) were significantly predictive factors for PSA-PFS. PSADT estimation remained accurate when calculated from PSA nadir values ≥0.5 ng/mL. Conclusions: In patients with nmCRPC with PSADT ≤ 10 months, early initiation of ARPIs at lower PSA levels was associated with improved PSA-PFS. PSADT stabilized at PSA levels of >0.5 ng/mL. These findings support earlier ARPI initiation to optimize outcomes in high-risk nmCRPC.
- Open Access
- 16 July 2025
- Published by Wolters Kluwer Health in Current Urology
- Vol. 19 (5) , 314-320
The efficacy of metastasis-directed external beam radiotherapy for castration-resistant prostate cancer: A retrospective multicenter study
Background: To assess the efficacy of metastasis-directed external beam radiotherapy (MDT) in patients with castration-resistant prostate cancer (CRPC), we conducted a multicenter retrospective study. Materials and methods: We retrospectively analyzed data from patients with metastatic CRPC treated with MDT between January 2013 and July 2023 across 14 hospitals. Patients who received palliative or local radiation therapy or had insufficient clinical data were excluded. The primary endpoint was the change in prostate-specific antigen (PSA) levels from pre- to post-MDT. Secondary endpoints included overall survival, time to next systemic therapy, PSA progression-free survival, and reduction of target lesions assessed radiographically. Results: Among 579 patients with metastatic prostate cancer who received radiation therapy, 48 underwent MDT. The median follow-up period was 325 days, and the median patient age was 74 years. Metastasis-directed external beam radiotherapy target sites included bone (n = 34, 70.8%), lymph nodes (n = 11, 22.9%), local recurrence (n = 2, 4.2%), and other sites (n = 1, 2.1%). Of the 48 patients, 30 (62.5%) showed a decrease in PSA levels after MDT, and 20 (41.6%) achieved a PSA reduction greater than 50%. Among the 26 patients who underwent post-MDT radiographic evaluation, 11 (42.3%) demonstrated a reduction in target lesions. Median overall survival, PSA progression-free survival, and time to next systemic therapy for patients with and without a PSA response were 1307 versus 614 days (p = 0.038, log-rank test), 233 versus 98 days (p = 0.014, log-rank test), and 434 versus 450 days (p = 0.273, log-rank test), respectively. The median PSA doubling time was 4.1 months in PSA responders and 1.7 months in nonresponders. Conclusions: Metastasis-directed external beam radiotherapy resulted in PSA reduction in 62.5% of patients with metastatic CRPC. Metastasis-directed external beam radiotherapy may be a suitable treatment option for patients with a favorable prognosis but may not benefit those with a poor prognosis and short PSA doubling time.
- 16 July 2025
- Published by Wolters Kluwer Health in Current Urology
- Vol. 19 (5) , 314-320
Open AccessThe efficacy of metastasis-directed external beam radiotherapy for castration-resistant prostate cancer: A retrospective multicenter study
Background: To assess the efficacy of metastasis-directed external beam radiotherapy (MDT) in patients with castration-resistant prostate cancer (CRPC), we conducted a multicenter retrospective study. Materials and methods: We retrospectively analyzed data from patients with metastatic CRPC treated with MDT between January 2013 and July 2023 across 14 hospitals. Patients who received palliative or local radiation therapy or had insufficient clinical data were excluded. The primary endpoint was the change in prostate-specific antigen (PSA) levels from pre- to post-MDT. Secondary endpoints included overall survival, time to next systemic therapy, PSA progression-free survival, and reduction of target lesions assessed radiographically. Results: Among 579 patients with metastatic prostate cancer who received radiation therapy, 48 underwent MDT. The median follow-up period was 325 days, and the median patient age was 74 years. Metastasis-directed external beam radiotherapy target sites included bone (n = 34, 70.8%), lymph nodes (n = 11, 22.9%), local recurrence (n = 2, 4.2%), and other sites (n = 1, 2.1%). Of the 48 patients, 30 (62.5%) showed a decrease in PSA levels after MDT, and 20 (41.6%) achieved a PSA reduction greater than 50%. Among the 26 patients who underwent post-MDT radiographic evaluation, 11 (42.3%) demonstrated a reduction in target lesions. Median overall survival, PSA progression-free survival, and time to next systemic therapy for patients with and without a PSA response were 1307 versus 614 days (p = 0.038, log-rank test), 233 versus 98 days (p = 0.014, log-rank test), and 434 versus 450 days (p = 0.273, log-rank test), respectively. The median PSA doubling time was 4.1 months in PSA responders and 1.7 months in nonresponders. Conclusions: Metastasis-directed external beam radiotherapy resulted in PSA reduction in 62.5% of patients with metastatic CRPC. Metastasis-directed external beam radiotherapy may be a suitable treatment option for patients with a favorable prognosis but may not benefit those with a poor prognosis and short PSA doubling time.
- Open Access
- 1 May 2018
- Published by Elsevier in Urology Case Reports
- Vol. 18, 22-25
A rare case of suspected intravascular large B-cell lymphoma forming nodular masses in the brain and around the prostate and seminal vesicle
- 1 May 2018
- Published by Elsevier in Urology Case Reports
- Vol. 18, 22-25
Open AccessA rare case of suspected intravascular large B-cell lymphoma forming nodular masses in the brain and around the prostate and seminal vesicle